Table 1.
Trials of RTX use in CTD-ILD.
| References | No of patients | Disease | RTX scheme | Follow up | Outcomes | Safety of RTX |
|---|---|---|---|---|---|---|
| Duarte et al. (7) | 30 | CTDs | RA scheme | 3 y | Improved FVC Stable DLCO | 13/30 pts discontinued RTX 4/13 due to infection |
| Lepri et al. (8) | 44 | CTDs | RA scheme | 1y/2y | Stable FVC and DLCO | 12/44 pts serious AE |
| Atienza-Mateo et al. (9) | 26 | CTDs | RA scheme (n = 20) Lymphoma scheme (n = 2) |
2 y | Stable PFTs at 6 m, 1, 2 y ↑DLCO at 1 y stable HRCT |
6/26 discontinued RTX due to AE 3/26 death |
| Sharp et al. (10) | 24 | CTDs | RA scheme | 6 m | Improved FVC stable DLCO 13/22 stable HRCT | No serious AE |
| Robles-Peres et al. (11) | 18 | CTDs | RA scheme | 1y/2y | Increased PFTs at 1 y 10/18 stable HRCT at 1 y |
No serious AE |
| Zhu et al. (13) | 15 RTX vs. 68 non-RTX | CTDs | Significant DLCO change and steroid reduction vs. control Similar FVC, HRCT score vs. control |
No serious AE | ||
| Keir et al. (12) | 33 | CTDs | RA scheme | 6 m/1 y | Improved FVC, stable DLCO | – |
| Mena-Vazquez et al. (14) | 37 | CTDs | RA scheme | 1 y | Stable PFTs HRCT stable or improved |
29/37 lung infection, 7/27 deaths |
No, Number; m, month; y, year; AE, adverse events; CTDs, connective tissue diseases; RTX, rituximab; PFTs, pulmonary function tests; FVC, forced vital capacity; DLCO, diffusing lung capacity for carbon monoxide; HRCT, high resolution computed tomography; RA, rheumatoid arthritis. ↑, Increased.